FDA Approves Bixlenvo for Virologically Suppressed HIV

The FDA approved a once-daily tablet combining bictegravir 75 mg and lenacapavir 50 mg (Bixlenvo, Gilead) as a complete replacement regimen for adults with HIV-1 who are virologically suppressed on stable therapy and have no known or suspected resistance to either component.

The regimen pairs an integrase strand transfer inhibitor with a capsid inhibitor that acts at multiple stages of the viral life cycle. It is intended in part for patients seeking to simplify complex multidrug regimens.

Approval was supported by the phase 3 ARTISTRY-1 and ARTISTRY-2 trials. In both studies, switching to bictegravir-lenacapavir maintained virologic suppression at week 48 at rates comparable with continued complex therapy or Biktarvy. ARTISTRY-1 participants had a median age of 60 years, a median treatment history of 28 years, and substantial prior nucleoside reverse transcriptase inhibitor resistance.

The most common adverse reactions across the program were headache, nausea, and diarrhea. Bixlenvo is contraindicated with dofetilide and strong CYP3A inducers, and clinicians must assess clinically important drug interactions. Treatment begins with a two-day initiation regimen that also includes oral Sunlenca before once-daily Bixlenvo maintenance.

The approval expands single-tablet options for selected treatment-experienced adults while preserving the requirement for resistance review and careful interaction management.

Source: Gilead Sciences, Inc. U.S. FDA Approves Gilead’s Bixlenvo, a New Once-Daily Single Tablet Option for Virologically Suppressed Adults With HIV, Including Those on Complex Regimens. Published August 27, 2026. Accessed August 30, 2026.